Cargando…
Monobodies as tool biologics for accelerating target validation and druggable site discovery
Despite increased investment and technological advancement, new drug approvals have not proportionally increased. Low drug approval rates, particularly for new targets, are linked to insufficient target validation at early stages. Thus, there remains a strong need for effective target validation tec...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
RSC
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597423/ https://www.ncbi.nlm.nih.gov/pubmed/34820623 http://dx.doi.org/10.1039/d1md00188d |